The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

That locked up the obesity drug. But after 9 Meters started ... Wegovy, for example, "doesn't really work" — at least to the Food and Drug Administration standard of weight loss of 5% or more ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Here’s what to know about ultra-processed foods, and how Kennedy has said he plans to shape the U.S. food system.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

The U.S. Food and Drug Administration (FDA ... Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...